Wall Street Zen Downgrades Turn Therapeutics (NASDAQ:TTRX) to Sell

Turn Therapeutics (NASDAQ:TTRX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. WBB Securities reaffirmed a “sell” rating and set a $10.00 price target on shares of Turn Therapeutics in a report on Monday, September 14th. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Finally, LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Price Performance

Shares of TTRX stock opened at $12.49 on Friday. The business has a fifty day simple moving average of $10.66 and a 200 day simple moving average of $7.02. The company has a market cap of $372.08 million and a P/E ratio of -43.07. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last released its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TTRX. Ieq Capital LLC acquired a new position in Turn Therapeutics in the 2nd quarter valued at approximately $1,660,000. BlackRock Inc. acquired a new position in shares of Turn Therapeutics during the second quarter worth $282,000. Bridgewater Advisors Inc. acquired a new position in shares of Turn Therapeutics during the second quarter worth $242,000. DDFG Inc grew its stake in shares of Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after purchasing an additional 18,246 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Turn Therapeutics in the second quarter worth $119,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.